If biotech had a Mount Rushmore, whose heads would you chisel in the granite?
If someone sculpted a Mount Rushmore of biotech CEOs, who’d be on it?
The question struck me last week as I was considering the legacy of Vertex Pharma CEO Jeff Leiden upon his retirement. Leiden’s eight-year run at Vertex was a boon for cystic fibrosis patients and shareholders. His tenure could be viewed as record-breaking, but was it historic enough to cast his visage in granite?
